102791-96-8

Basic information

• Product Name: 1-(3-methyl-4-nitrophenyl)-1H-1,2,4-triazole
• Synonyms: 1-(3-methyl-4-nitrophenyl)-1H-1,2,4-triazole
• CAS NO: 102791-96-8
• Molecular Weight: 204.188
• Mol File: 102791-96-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(3-methyl-4-nitrophenyl)-1H-1,2,4-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-methyl-4-nitrophenyl)-1H-1,2,4-triazole(102791-96-8)
• EPA Substance Registry System: 1-(3-methyl-4-nitrophenyl)-1H-1,2,4-triazole(102791-96-8)

Safety Data

• Hazardous Substances Data: 102791-96-8(Hazardous Substances Data)

Upstream product

• 1538611-93-6 1-(3-methylphenyl)-1H-1,2,4-triazole 
• 625-95-6 3-Iodotoluene 
• 288-88-0 1,2,4-Triazole 
• 446-33-3 5-Fluoro-2-nitrotoluene 

Downstream Products

• 102791-90-2 2-methyl-4-[1,2,4]triazol-1-yl-phenylamine 
• 102791-83-3 (E)-3-Ethoxy-N-(2-methyl-4-[1,2,4]triazol-1-yl-phenyl)-acrylamide 

Relevant articles and documents

Triazole-substituted nitroarene derivatives: Synthesis, characterization, and energetic studies

A series of dense and energetic polynitroaryl-1,2,4-triazoles were synthesized through the nitration of aryl-1,2,4-triazoles. The Cu-catalyzed/base-mediated coupling reactions of haloarenes with 1,2,4-triazoles delivered N-aryl-1,2,4-triazoles. These new

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.

Tetrahydroimidazoquinazolinone inotropic agents

A series of novel heterocyclic-substituted 1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one compounds have been prepared, including their pharmaceutically acceptable salts, wherein the heterocyclic ring moiety is an optionally substituted 5- or 6-membered aromatic heterocyclic group attached to the 6-, 7-, 8- or 9-positions of the aforesaid tetrahydroquinaxolinone ring. These particular compounds are useful in therapy as highly potent inotropic and therefore, are of value in the treatment of various cardiac conditions. Preferred member compounds include 7-(2,4-dimethylimidaxol-1-yl)-9-methyl-1,2,4,5,-tetrahydroimidazo (2,1-b)quinazolin-2-(1H)-one, 3,9-dimethyl-7-(2,4-dimethylimidazol-1-yl) -1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one and 9-methyl-7 -(1,2,4-triazol-4-yl)-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one, respectively. Methods for preparing these compounds from known starting materials are provided.